Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
1 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
1 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
35441
Complement to Fig 7—A p53-dependent response promotes tissue development when nuclear reassembly is compromised.
Published 2024“…Right: Quantifications of wing sizes (<i>n</i> = 13 to 15). Scale bar: 1 mm. In panels A and B, Ankle2 RNAi line #1 (VDRC100655) was used. …”
-
35442
-
35443
-
35444
-
35445
RPS reduced the size and number of tumors on the esophagus of rats exposed to NMBA.
Published 2015“…The average number of papilloma and carcinoma is presented, n = 10. * represents significant difference between NMBA group vs healthy control group, <i>P</i> < 0.01. # represents significant difference between NMBA +RPS group vs NMBA group, <i>P</i> < 0.01.…”
-
35446
-
35447
-
35448
Use of Patient-Specific Instrumentation (PSI) for glenoid component positioning in shoulder arthroplasty. A systematic review and meta-analysis
Published 2018“…</p><p>Conclusion</p><p>This review supports the idea that PSI enhances glenoid component positioning, especially a decrease in the number of outliers. However, the findings are not definitive and further validation is required. …”
-
35449
-
35450
Table_1_Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab.docx
Published 2021“…The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058).</p>Conclusions<p>A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.…”
-
35451
-
35452
-
35453
-
35454
-
35455
-
35456
-
35457
-
35458
-
35459
-
35460
MiR-210 negatively regulates aconitase and complex I activity in MCF7 and HCT116, and upregulates glycolysis.
Published 2010“…<p>Cells transfected with siRNA against ISCU or with mimic-210 show a significant decrease in the activity of the Fe-S protein aconitase (<i>A</i>) and complex I (<i>B</i>) at 48 hrs. …”